Isolation of Multipotent Cells from Human Term Placenta

Abstract

Current sources of stem cells include embryonic stem cells (ESCs) and adult stem cells (ASCs). However, concerns exist with either source: ESCs, with their significant ethical considerations, tumorigenicity, and paucity of cell lines; and ASCs, which are possibly more limited in potential. Thus, the search continues for an ethically conducive, easily accessible, and high-yielding source of stem cells. We have isolated a population of multipotent cells from the human term placenta, a temporary organ with fetal contributions that is discarded postpartum. These placenta-derived multipotent cells (PDMCs) exhibit many markers common to mesenchymal stem cells-including CD105/endoglin/SH-2, SH-3, and SH-4-and they lack hematopoietic-, endothelial-, and trophoblastic-specific cell markers. In addition, PDMCs exhibit ESC surface markers of SSEA-4, TRA-1-61, and TRA-1-80. Adipogenic, osteogenic, and neurogenic differentiation were achieved after culturing under the appropriate conditions. PDMCs could provide an ethically uncontroversial and easily accessible source of multipotent cells for future experimental and clinical applications. Stem Cells 2005;23:3-9

Potential of Human Fetal Chorionic Stem Cells for the Treatment of Osteogenesis Imperfecta

“…For example, it is essential to have a source of stem cells that have high therapeutic potential and are easily accessible for clinical use. Extra-embryonic fetal tissues, such as the placenta, are readily available either from termination of pregnancy or surplus tissue at routine prenatal diagnostic procedures [17,18], or at term delivery [19,[20][21][22]. Recently, we have shown human fetal early chorionic stem cells (e-CSC) isolated from human placental tissue accelerated tissue repair in dermal excision skin wounds and improved bone quality and plasticity in oim mice.…”

Cardiac Repair Using Stem Cells Conditioned Media Based Therapy in a Rodent Model of Myocardial Infarction and Heart Failure

“…Yen BL and colleagues at the Institute of Cellular and System Medicine (Zhunan, Taiwan). MSC's were isolated using previously described protocols 61 . These cells were cultured in T75 TC flasks in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 ū/ml penicillin (Invitrogen, Carlsbad, CA).…”

“…We elected to inject the growth-factor containing cell passage media from both stem cell lines into the peri-infarct area, rather than graft the stem cells for several HiPSCs and extract from fractionated bone marrow stem cells in murine models 35,61 .…”

Age-Related Decreases of Serum-Response Factor Levels in Human Mesenchymal Stem Cells Are Involved in Skeletal Muscle Differentiation and Engraftment Capacity

“…Increasing number of reports show that fetal tissue and fetal extraembryonic tissues such as umbilical cord and placenta are good sources for MSCs [6,[8][9][10][11]. These developmentally early stage mesenchymal stem cells (DE-MSCs) can be isolated without performing additional invasive procedures, and these are more proliferative than adult BMMSCs [12,13].…”

“…These developmentally early stage mesenchymal stem cells (DE-MSCs) can be isolated without performing additional invasive procedures, and these are more proliferative than adult BMMSCs [12,13]. Moreover, many DE-MSCs express markers associated with embryonic stem cells (ESCs), likely due to the closer developmental origin of these MSCs to ESCs [11,14]. While it is known that increasing donor age of BMMSCs can limit the therapeutic applicability of these adult-source MSCs by enhancing adipogenic differentiation capacity at the expense of decreasing osteogenic differentiation capacity [15][16][17], little is known whether muscle differentiation capacity may be affected as well.…”